Acasti Pharma Inc. (ACST)
NASDAQ: ACST
· Real-Time Price · USD
3.37
0.13 (4.01%)
At close: Oct 25, 2024, 10:00 PM
Company Description
Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases.
It is evaluating strategic partnerships for the clinical development of CaPre.
The company was incorporated in 2002 and is headquartered in Laval, Canada.
Acasti Pharma Inc.
| Country | CA |
| IPO Date | Feb 7, 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 32 |
| CEO | Prashant Kohli |
Contact Details
Address: 3009 boulevard de la Concorde East Laval, QC CA | |
| Website | https://www.acastipharma.com |
Stock Details
| Ticker Symbol | ACST |
| Exchange | NASDAQ |
| Fiscal Year | April - March |
| Reporting Currency | USD |
| CIK Code | 0001444192 |
| CUSIP Number | 00430K402 |
| ISIN Number | CA00430K8656 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Prashant Kohli | Chief Executive Officer & Director |
| Amresh Kumar Ph.D. | Vice President of Program Management |
| Carrie D'Andrea | Vice President of Clinical Operations |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 14, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Aug 12, 2025 | 8-K | Current Report |
| Aug 12, 2025 | 10-Q | Quarterly Report |
| Jul 28, 2025 | DEFA14A | Filing |
| Jul 28, 2025 | DEF 14A | Filing |
| Jun 25, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 8-K | Current Report |
| Jun 23, 2025 | 10-K | Annual Report |
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 15, 2025 | SCHEDULE 13G | Filing |